PharmaCielo Ltd. PCLOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 330.85% | 1,236.23% | -45.99% | -33.75% | -59.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 330.85% | 1,236.23% | -45.99% | -33.75% | -59.30% |
| Cost of Revenue | 127.40% | -33.28% | -161.99% | 43.36% | -25.52% |
| Gross Profit | 952.85% | 138.59% | 108.76% | -232.28% | -121.86% |
| SG&A Expenses | 37.39% | -24.15% | -68.76% | 72.60% | -56.85% |
| Depreciation & Amortization | 414.48% | -87.74% | -80.67% | 1.15% | -60.81% |
| Other Operating Expenses | 67.65% | 3,640.63% | -418.48% | -26.04% | -703.75% |
| Total Operating Expenses | 94.89% | 28.20% | -164.89% | 59.11% | -57.23% |
| Operating Income | 8.74% | 18.48% | 504.08% | -200.58% | 56.25% |
| Income Before Tax | -10.50% | 42.80% | 127.22% | 48.09% | 50.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.50% | 42.80% | 127.22% | 48.09% | 50.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.50% | 42.80% | 127.22% | 48.09% | 50.03% |
| EBIT | 8.74% | 18.48% | 504.08% | -200.58% | 56.25% |
| EBITDA | -27.51% | 58.81% | 2,019.00% | -204.43% | 72.68% |
| EPS Basic | 0.00% | 44.44% | 126.23% | 55.00% | 54.95% |
| Normalized Basic EPS | -3.23% | 60.71% | 126.32% | -100.00% | 55.07% |
| EPS Diluted | 0.00% | 44.44% | 126.23% | 55.00% | 54.95% |
| Normalized Diluted EPS | -3.23% | 60.71% | 126.32% | -100.00% | 55.07% |
| Average Basic Shares Outstanding | 10.11% | 3.02% | 7.25% | 16.02% | 10.74% |
| Average Diluted Shares Outstanding | 10.11% | 3.02% | 7.25% | 16.02% | 10.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |